Search clinical trials for: ALK-positive NSCLC

Total 3609 results

Zhejiang University

Recruiting

A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

Unresectable Lung Non-Small Cell Carcinoma

China
Memorial Sloan Kettering Cancer Center
Varian Medical Systems

Recruiting

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Melanoma | Sarcoma | Renal Cell Carcinoma | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Metastatic Solid Tumor | Gastrointestinal Cancer | Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma | Gastrointestinal Adenocarcinoma | Invasive Ductal Breast Carcinoma Stage IV | Lobular... and other conditions

United States
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
LUNGevity Foundation
Bristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Novartis; T... and other collaborators

Recruiting

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting (PEER)

Caregivers | Lung Cancer Patients

United States
Guangzhou Institute of Respiratory Disease

Recruiting

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Poor Performance Status | Malignant Tumor of Lung

China
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG; Thoraxklinik-Heidelberg gGmbH

Recruiting

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Non-small Cell Lung Cancer

Germany
RemeGen Co., Ltd.

Recruiting

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NSCLC

China
Second Xiangya Hospital of Central South University
Geneplus-Beijing Co. Ltd.

Not yet recruiting

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Non-small Cell Lung Cancer

China
Kai-Uwe Schmitt, PhD, MEng, ICID

Recruiting

Digital Lifestyle Intervention for Lung Cancer Survivors After Inpatient Rehabilitation (QUALUCA)

Non-Small Cell Lung Cancer (NSCLC)

Switzerland
NYU Langone Health

Recruiting

Ladarixin With Sotorasib in Advanced NSCLC

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

United States
Klus Pharma Inc.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China, Spain, Turkey, Georgia, Korea, Republic of, Australia, Romania
Columbia University

Not yet recruiting

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Non Small Cell Lung Cancer

United States
Three Gorges Hospital of Chongqing University

Recruiting

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases (SUPER BRAIN)

Bevacizumab | Brain Metastases | Immunotherapy | Non-small Cell Lung Cancer Stage II

China
Centre hospitalier de l'Université de Montréal...

Recruiting

Dietary Intervention for NSCLC Patients Treated With ICI

Non Small Cell Lung Cancer

Canada
Taipei Veterans General Hospital, Taiwan

Not yet recruiting

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Carcinoma, Non-Small-Cell Lung | Leptomeningeal Metastasis | Epidermal Growth Factor Receptor
NYU Langone Health

Recruiting

Daratumumab in STK11 Mutated NSCLC

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

United States
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA)

Non-Small Cell Lung Cancer (NSCLC)

Korea, Republic of, Malaysia, Taiwan, Thailand, Hong Kong, Singapore, Canada
Shanghai Chest Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

NSCLC

China
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States, Malaysia, Australia, Georgia, Israel, Canada
BGI, China
Fudan University; Shanghai 10th People's Hospital

Recruiting

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Solid Tumor

China
BGI, China
Wuhan Union Hospital, China

Recruiting

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Solid Tumor

China
Alliance Foundation Trials, LLC.
Genentech, Inc.

Recruiting

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

NSCLC

United States
Black Diamond Therapeutics, Inc.

Recruiting

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Melanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditions

United States
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (TEMPLE-2)

Non Small Cell Lung Cancer

Italy
DualityBio Inc.

Recruiting

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

United States, China
Washington University School of Medicine
Varian Medical Systems

Recruiting

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Early Stage Non-small Cell Lung Cancer

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States, Israel, Malaysia, Australia, Georgia, Turkey, Canada
Jiangsu Cancer Institute & Hospital

Not yet recruiting

Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC

Non-squamous NSCLC

China
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE)

Non Small Cell Lung Cancer

France
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC; Merck Serono GmbH, Germany

Recruiting

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (POTENT)

Non Small Cell Lung Cancer | Advanced Cancer

United Kingdom
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Non-small Cell Lung Cancer

China
Fudan University

Recruiting

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Non-small Cell Lung Cancer | Neoadjuvant Therapy | Immunotherapy | Stage II-IIIA

China
National Cancer Centre, Singapore
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NSCLC

Singapore
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZB-0004 in Patients With Solid Tumors

NSCLC | Advanced Solid Tumor

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
Sun Yat-sen University

Recruiting

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Brain Metastases | Radiotherapy | EGFR Activating Mutation

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Recruiting

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Treatment Side Effects | Treatment

China
Pingping Song

Not yet recruiting

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer(NSCLC)

China
Taiho Oncology, Inc.

Recruiting

A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351)

Non-Small Cell Lung Cancer

United States, France, Italy, Korea, Republic of, Japan, Spain, Germany, Netherlands, United Kingdom
Peking University Cancer Hospital & Institute

Recruiting

Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Non-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential Chemoradiation

China
Biotheus Inc.

Recruiting

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

NSCLC

China
Indiana University

Recruiting

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

NSCLC, Stage III

United States
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Advance Non-small Cell Lung Cancer

Spain, Italy, Greece
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Non-small Cell Lung Cancer

China
Xinqiao Hospital of Chongqing

Recruiting

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Lung Cancer | Radiotherapy | Immune Checkpoint Inhibitor

China
Shanghai Chest Hospital
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Non-squamous NSCLC

China

Search clinical trials for: ALK-positive NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations